Genetics point to 89 existing drugs that could help systemic sclerosis

Credibility

Interest

Key Takeaway

Researchers used human genetics to find 89 existing drugs that might help treat systemic sclerosis, highlighting new targets including inflammation, hormones, and unexpected nerve-related medicines.

What They Found

The team searched genetic studies linked to systemic sclerosis and matched the genes found to known drug targets, producing a list of 89 existing drugs that could be tested for this disease.These drugs fall into three main groups: ones affecting female sex hormones, ones that act on nerve signaling (neurotransmitters), and drugs that calm inflammation and scarring (fibrosis).One promising target is the JAK/STAT pathway, a chain of molecules inside cells that can drive inflammation and scarring; drugs that block this chain are already used in other diseases and could help in systemic sclerosis.A drug named amlitelimab, which blocks a molecule called OX40L, is already being tested in a clinical trial for lung-related systemic sclerosis, showing that this genetic approach points to real treatments being tried now.The discovery that many neurotransmitter-related drugs might help is new and could explain or help treat symptoms like Raynaud’s (where fingers/toes get very cold and change color) and gut problems, since nerves help control blood flow and digestion.

Who Should Care and Why

People with systemic sclerosis and their caregivers should care because these findings point to existing medicines that might be repurposed, which can be faster and cheaper to test than brand-new drugs—kind of like trying a proven tool on a new problem.Patients with lung scarring or Raynaud’s could especially benefit if these identified drugs reduce inflammation, protect tissues, or improve blood flow to hands and feet.Caregivers and family members can use this information to ask doctors about ongoing trials or whether any off-label options are appropriate; knowing that research points to familiar drug types makes conversations easier.Healthcare providers may use these prioritized targets to plan trials or consider compassionate use in certain cases, because the list flags drugs with genetic reasons to help systemic sclerosis rather than guessing.Because many candidate drugs are already widely available and affordable, successful repurposing could lead to quicker relief for symptoms without long waits for brand-new treatments.

Important Considerations

This study is a research-prioritization effort, not proof that these drugs work for systemic sclerosis—clinical trials are still needed to show benefit and safety for people with this condition.Genetic links suggest a drug might help, but that doesn’t guarantee it will; other factors like side effects, dose, and how the drug acts in whole people matter a lot.Some drugs identified are not yet tested in systemic sclerosis and some findings are unexpected (like nerve-related drugs), so patients should not try treatments on their own and should discuss options with their medical team.

Categories:

MS Genetics Early Research Treatment Updates

Article Topics:

clinical trialsdrug repurposingsclerodermasystemic sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Rheumatology (Oxford, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News